1. Epigenetics
  2. PKC
  3. Delcasertib

Delcasertib (Synonyms: KAI-9803; BMS-875944)

Cat. No.: HY-106262 Purity: 95.38%
Handling Instructions

Delcasertib (KAI-9803) is a potent and selective δ-protein kinase C (δPKC) inhibitor.

For research use only. We do not sell to patients.

Delcasertib Chemical Structure

Delcasertib Chemical Structure

CAS No. : 949100-39-4

Size Price Stock Quantity
10 mM * 1 mL in DMSO USD 2522 In-stock
Estimated Time of Arrival: December 31
5 mg USD 650 In-stock
Estimated Time of Arrival: December 31
10 mg USD 990 In-stock
Estimated Time of Arrival: December 31
25 mg USD 1990 In-stock
Estimated Time of Arrival: December 31
50 mg USD 2750 In-stock
Estimated Time of Arrival: December 31
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 1 publication(s) in Google Scholar

Top Publications Citing Use of Products
  • Biological Activity

  • Protocol

  • Purity & Documentation

  • References

  • Customer Review


Delcasertib (KAI-9803) is a potent and selective δ-protein kinase C (δPKC) inhibitor.

IC50 & Target



In Vitro

Delcasertib (KAI-9803) is composed of a selective δ-protein kinase C (δPKC) inhibitor peptide derived from the δV1-1 portion of δPKC (termed “cargo peptide”), conjugated reversibly to the cell-penetrating peptide 11-amino acid, arginine-rich sequence of the HIV type 1 transactivator protein (TAT47–57; termed “carrier peptide”) via a disulfide bond[1].

In Vivo

Delcasertib (KAI-9803) administration at the end of ischemia has been found to reduce cardiac damage caused by ischemia-reperfusion in a rat model of acute myocardial infarction. 14C-KAI-9803 is rapidly delivered to many tissues, including the heart (1.21 μg eq/g tissue), while being quickly cleared from the systemic circulation. The distribution of Delcasertib (KAI-9803) to tissues such as the liver, kidney, and heart is facilitated by the reversible conjugation to TAT47–57[1]. KAI-9803 ameliorates pathological conditions in acute myocardial infarction and reduce pain via specific modulation of membrane-translocation of PKC delta or epsilon. Delcasertib (KAI-9803) has an acceptable safety and tolerability profile when delivered via intracoronary injection during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction[2].

Clinical Trial
Molecular Weight







OC(C=C1)=CC=C1C[[email protected]](NC([[email protected]](CO)NC([[email protected]](CC(N)=O)NC([[email protected]@H](NC([[email protected]](CO)NC([[email protected]@H](N)CSSC[[email protected]](N)C(N[[email protected]](C(NCC(N[[email protected]@H](CCCNC(N)=N)C(N[[email protected]@H](CCCCN)C(N[[email protected]@H](CCCCN)C(N[[email protected]@H](CCCNC(N)=N)C(N[[email protected]@H](CCCNC(N)=N)C(N[[email protected]@H](CCC(N)=O)C(N[[email protected]@H](CCCNC(N)=N)C(N[[email protected]@H](CCCNC(N)=N)C(N[[email protected]](C(O)=O)CCCNC(N)=N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CC2=CC=C(O)C=C2)=O)=O)=O)CC3=CC=CC=C3)=O)=O)=O)C(N[[email protected]@H](CCC(O)=O)C(N[[email protected]@H](CC(C)C)C(NCC(N[[email protected]@H](CO)C(N[[email protected]](C(O)=O)CC(C)C)=O)=O)=O)=O)=O


Room temperature in continental US; may vary elsewhere.

Powder -80°C 2 years
  -20°C 1 year
In solvent -80°C 6 months
  -20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : ≥ 100 mg/mL (34.72 mM)

*"≥" means soluble, but saturation unknown.

Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 0.3472 mL 1.7359 mL 3.4719 mL
5 mM 0.0694 mL 0.3472 mL 0.6944 mL
10 mM 0.0347 mL 0.1736 mL 0.3472 mL
*Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 7.69 mg/mL (2.67 mM); Clear solution

  • 2.

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (0.87 mM); Clear solution

  • 3.

    Add each solvent one by one:  10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (0.87 mM); Clear solution

*All of the co-solvents are provided by MCE.
Animal Administration


For pharmacokinetic studies, 14Delcasertib (KAI-9803) (1 mg/kg) is administered to Six-week-old male Crl:CD(SD) rats via the femoral vein and approximately 0.2 mL of blood is collected from the jugular vein at 1, 2, 5, 10, and 15 min postdose with a heparinized syringe containing 10 μL of 400 mM diisopropylfluorophosphate dissolved in acetonitrile to prevent rapid degradation of the peptide. The radioactivity in the blood and plasma samples is measured using a liquid scintillation counter[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2


DelcasertibKAI-9803BMS-875944KAI9803KAI 9803BMS875944BMS 875944PKCProtein kinase CInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product name



Applicant name *


Email address *

Phone number *


Organization name *

Country or Region *


Requested quantity *


Bulk Inquiry

Inquiry Information

Product name:
Cat. No.:
MCE Japan Authorized Agent: